Los puntos clave no están disponibles para este artículo en este momento.
Mycophenolate mofetil was superior to azathioprine in maintaining a renal response to treatment and in preventing relapse in patients with lupus nephritis who had a response to induction therapy. (Funded by Vifor Pharma formerly Aspreva; ALMS ClinicalTrials.gov number, NCT00377637.).
Dooley et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: